| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 240 | 200 | 60 | 0 | 0 |
| Sales Growth | +20.00% | +233.34% | unch | unch | unch |
| Net Income | -2,740 | -3,530 | -3,060 | -3,010 | -1,830 |
| Net Income Growth | +22.38% | -15.36% | -1.66% | -64.48% | +39.80% |
Coeptis Therapeutics Hldgs Inc (COEP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp., is based in WEXFORD, Pa.
Fiscal Year End Date: 12/31